{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:39:09Z","timestamp":1790404749383,"version":"4.1.0"},"reference-count":26,"publisher":"Japan Neurosurgical Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2017]]},"DOI":"10.2176\/nmc.cr.2016-0330","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T22:27:28Z","timestamp":1490221648000},"page":"191-197","source":"Crossref","is-referenced-by-count":20,"title":["Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report"],"prefix":"10.2176","volume":"57","author":[{"given":"Motomasa","family":"FURUSE","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naosuke","family":"NONOGUCHI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"OMURA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"SHIRAHATA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"IWASAKI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"INUI","sequence":"additional","affiliation":[{"name":"Saisei Mirai Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"KUROIWA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"KUWABARA","sequence":"additional","affiliation":[{"name":"Department of Pathology, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ichi","family":"MIYATAKE","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Glass J, Gruber ML, Cher L, Hochberg FH: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. <i>J Neurosurg<\/i> 81: 188\u2013195, 1994","DOI":"10.3171\/jns.1994.81.2.0188"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hiraga S, Arita N, Ohnishi T, Kohmura E, Yamamoto K, Oku Y, Taki T, Sato M, Aozasa K, Yoshimine T: Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. <i>J Neurosurg<\/i> 91: 221\u2013230, 1999","DOI":"10.3171\/jns.1999.91.2.0221"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Reni M, Ferreri AJ, Villa E: Second-line treatment for primary central nervous system lymphoma. <i>Br J Cancer<\/i> 79: 530\u2013534, 1999","DOI":"10.1038\/sj.bjc.6690083"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA: Nivolumab in previously untreated melanoma without braf mutation. <i>New Engl J Med<\/i> 372: 320\u2013330, 2015","DOI":"10.1056\/NEJMoa1412082"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr., Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-ctla-4 treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncol<\/i> 16: 375\u2013384, 2015","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlh\u00e4ufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crin\u00f2 L, Blumenschein GR, Jr., Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. <i>N Engl J Med<\/i> 373: 1627\u20131639, 2015","DOI":"10.1056\/NEJMoa1507643"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. <i>New Engl j Med<\/i> 373: 123\u2013135, 2015","DOI":"10.1056\/NEJMoa1504627"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P: Nivolumab versus everolimus in advanced renal-cell carcinoma. <i>N Engl J Med<\/i> 373: 1803\u20131813, 2015","DOI":"10.1056\/NEJMoa1510665"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P: Pd-1 blockade with nivolumab in relapsed or refractory hodgkin\u2019s lymphoma. <i>New Engl J Med<\/i> 372: 311\u2013319, 2015","DOI":"10.1056\/NEJMoa1411087"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Batchelor T, Carson K, O\u2019Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R: Treatment of primary cns lymphoma with methotrexate and deferred radiotherapy: A report of nabtt 96-07. <i>J Clinical Oncol<\/i> 21: 1044\u20131049, 2003","DOI":"10.1200\/JCO.2003.03.036"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Reni M, Ferreri AJ, Guha-Thakurta N, Blay JY, Dell\u2019Oro S, Biron P, Hochberg FH: Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. <i>Int J Radiat Oncol Biol Phys<\/i> 51: 419\u2013425, 2001","DOI":"10.1016\/S0360-3016(01)01639-X"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Roth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithauser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, N\u00e4gele T, Pietsch T, Bamberg M, Weller M: High-dose methotrexate with or without whole brain radiotherapy for primary cns lymphoma (g-pcnsl-sg-1): A phase 3, randomised, non-inferiority trial. <i>Lancet Oncol<\/i> 11: 1036\u20131047, 2010","DOI":"10.1016\/S1470-2045(10)70229-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT: Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. <i>Clin Cancer Res<\/i> 10: 5643\u20135646, 2004","DOI":"10.1158\/1078-0432.CCR-04-0159"},{"key":"14","unstructured":"14) Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: A new classification. <i>Cancer Treat Rep<\/i> 65 Suppl 1: 89\u201398, 1981"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell\u2019Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ: Salvage chemotherapy with temozolomide in primary cns lymphomas: Preliminary results of a phase ii trial. <i>Eur J Cancer<\/i>. 40: 1682\u20131688, 2004","DOI":"10.1016\/j.ejca.2004.03.008"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide: <i>Neurology<\/i> 63: 901\u2013903, 2004","DOI":"10.1212\/01.WNL.0000137050.43114.42"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA: Association of pd-1, pd-1 ligands, and other features of the tumor immune microenvironment with response to anti-pd-1 therapy. <i>Clin Cancer Res<\/i> 20: 5064\u20135074, 2014","DOI":"10.1158\/1078-0432.CCR-13-3271"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Meng X, Huang Z, Teng F, Xing L, Yu J: Predictive biomarkers in pd-1\/pd-l1 checkpoint blockade immunotherapy. <i>Cancer Treat Rev<\/i> 41: 868\u2013876, 2015","DOI":"10.1016\/j.ctrv.2015.11.001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ: Mpdl3280a (anti-pd-l1) treatment leads to clinical activity in metastatic bladder cancer. <i>Nature<\/i> 515: 558\u2013562, 2014","DOI":"10.1038\/nature13904"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Cali\u00f2 A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E, Tortora G: Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers. <i>PLoS One<\/i> 10: e0130142, 2015","DOI":"10.1371\/journal.pone.0130142"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J: Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. <i>J Clin Oncol<\/i> 34: 2698\u2013704, 2016","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Furuse M, Kawabata S, Kuroiwa T, Miyatake S: Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. <i>J Neurooncol<\/i> 102: 471\u2013475, 2011","DOI":"10.1007\/s11060-010-0333-3"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Furuse M, Nonoguchi N, Kawabata S, Yoritsune E, Takahashi M, Inomata T, Kuroiwa T, Miyatake S: Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid pet. <i>Jpn J Clin Oncol<\/i> 43: 337\u2013341, 2013","DOI":"10.1093\/jjco\/hys231"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Furuse M, Nonoguchi N, Kuroiwa T, Miyamoto S, Arakawa Y, Shinoda J, Miwa K, Iuchi T, Tsuboi K, Houkin K, Terasaka S, Tabei Y, Nakamura H, Nagane M, Sugiyama K, Terasaki M, Abe T, Narita Y, Saito N, Mukasa A, Ogasawara K, Beppu T, Kumabe T, Nariai T, Tsuyuguchi N, Nakatani E, Kurisu S, Nakagawa Y, Miyatake SI: A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. <i>Neuro Oncol Pract<\/i> 3: 272\u2013280, 2016","DOI":"10.1093\/nop\/npv064"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Nieto K, Gordon LI, Raizer J: Bevacizumab for recurrent primary central nervous system lymphoma: A new treatment? <i>Neuro Oncol<\/i> 17: 1648\u20131649, 2015","DOI":"10.1093\/neuonc\/nov246"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Palucka K, Banchereau J: Cancer immunotherapy via dendritic cells. <i>Nat Rev Cancer<\/i> 12: 265\u2013277, 2012","DOI":"10.1038\/nrc3258"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/57\/4\/57_cr.2016-0330\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T13:14:38Z","timestamp":1498396478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/57\/4\/57_cr.2016-0330\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2176\/nmc.cr.2016-0330","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"value":"0470-8105","type":"print"},{"value":"1349-8029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}